Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents

European Journal of Medical Research

Volumn 11, Issue 8, 2006, Pages 313-321

  Pogrebniak, A ^a   Schemainda, I ^b   Azzam, K ^c   Pelka Fleischer, R ^c   Nüssler, Volkmar ^c,e   Hasmann, M ^d  

^a UNIVERSITY OF ULM   (Germany)

^b Astellas Pharma GmbH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d ROCHE DIAGNOSTICS GMBH   (Germany)

^e Tumorzentrum München ^*  (Germany)

Author keywords

Apoptosis; FK866; Melphalan; MNNG; NAD

Indexed keywords

3 AMINOBENZAMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; APO 866; CELL DNA; CYTARABINE; DAUNORUBICIN; FK 866; MELPHALAN; METHYLNITRONITROSOGUANIDINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NICOTINATE PHOSPHORIBOSYLTRANSFERASE; PROPIDIUM IODIDE; PROTEIN SYNTHESIS INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL STRAIN K 562; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LEUKEMIA CELL LINE; MALIGNANT NEOPLASTIC DISEASE; PROTEIN DEPLETION; PROTEIN SYNTHESIS INHIBITION; TIME;

ACRYLAMIDES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CYTARABINE; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; K562 CELLS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; MELPHALAN; METHYLNITRONITROSOGUANIDINE; MONOCYTES; NAD; PIPERIDINES;

EID: 33748707427     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Martin D.S. Biochemical modulation: perspectives and objectives. In: K.R. Harrap (ed.) New avenues in developmental cancer therapy, pp.113-162. London, Academic press, 1996
2. Martin D.S., Bertino J.R., Koutcher J.A. ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. Cancer Res. 60; 6776-6783, 2000
3. Althaus FR, Richter C. ADP-ribosylation of proteins: enzymology and biological significance. Mol Biol Biochem Biophys. 37: 1-125, 1987
4. + and ATP levels during ricin-induced apoptosis through the specific ribosomal inactivation results in the cytolysis of U937 cells. J Biochem 128: 463-470
5. Varnes M.E. Inhibition of pentose cycle of A54 cells by 6-aminonicotinamide: consequences for aerobic and hypoxic radiation response and for radiosensitizer action. Natl. Cancer Inst. Monogr. 6; 199-202, 1988
6. Pogrebniak A, Hasmann M, Schemainda I, Pelka-Fleischer R, Nuessler V. Cytoprotective features of selenazofurin in hematopoietic cells. Int J Clin Pharmacol Ther. 2002 Aug;40(8):368-75.
7. Boulton S, Kyle S, Durkacz BW. Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair. Br J Cancer. 1997;76(7):845-51.
8. Hasmann M, Schemainda I. FK866, a highly specific non-competitive inhibitor of nicotinamide phosphoribosyl-transferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003 Nov 1;63(21): 7436-42.
9. Wosikowski K, Mattern K, Schemainda I, Hasmann M, Rattel B, Loser R. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res. 2002 Feb 15;62(4): 1057-62.
10. d'Amours D., Desnoyers S., d'Silva I., Poirier G. Poly-(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 342; 249-268, 1999
11. Berger N.A., Berger S.J., Catino D.M., Petzold S.J., Robins R.K. Modulation of nicotinamide adenine dinucleotide and poly(adenosinediphosphoribose) metabolism by the synthetic "C" nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy. J. Clin. Invest. 75; 702-709, 1985
12. Kehrer J.P., Lund L.G. Cellular reducing equivalents and oxidative stress. Free Radic. Biol. Med. 17; 65-75, 1994
13. Pratt W.B., Ruddon R.W., Ensminger W.D., Maybaum J. Covalent DNA binding drugs: nitrogen mustards, aziridines, alkane sulfonates, nitrosouteas, platinum compounds, and monoalkylating agents. In: The anticancer drugs, 108-154. New York: Oxford university press, 1994
14. 2-induced apoptosis. Exp. Cell Res. 221; 462-469, 1995
15. Simbulan-Rosenthal C.M., Rosenthal D.S., Iyer S., Boulares A.H., Smulson M.E. Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose)polymerase in early stages of apoptosis. J. Biol. Chem. 273; 13703-13712, 1998
16. Pogrebniak A, Schemainda I, Pelka-Fleischer R, Nussler V, Hasmann M. Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects. Eur J Med Res. 2003 Oct 22;8(10):438-50.